Business Wire

Anubi Digital Brings Its High Net Worth Customers New Ways to Grow Their Digital Assets Through New Partnership With Celsius

Share

Anubi Digital, a digital asset custodian and the first company in Italy to provide access to institutional decentralized finance (DeFi), along with Celsius, the world's leading cryptocurrency platform, have entered into an agreement to expand crypto service offerings for Anubi Digital’s customers.

The service will allow Anubi Digital’s users to be screened and verified in advance and have their digital assets guaranteed for security and compliance.

Anubi Digital offers custom strategies and will also have access to a range of tax and legal services covering the full crypto lifecycle which helps position their crypto assets for long-term, sustainable growth.

With over $20 billion in assets, Celsius is a global leader in crypto and its services are considered as the benchmark of the industry.

"We are very proud of our partnership with Celsius. After being the first player to bring institutional DeFi to Italy, giving our clients the opportunity to enter the crypto vertical, this new partnership with Celsius allows us to offer best-in-class CeFi solutions to the marketsaid Diego D'Aquilio, CEO and Co-Founder of Anubi Digital.

At Celsius our goal is to bring financial freedom to the masses and through this partnership we further this commitment,”said Alex Mashinsky, CEO at Celsius. “Anubi Digital has been able to merge best-in-class crypto services with custom solutions for high net worth individuals, and we are proud to be part of that growth.”

ABOUT CELSIUS NETWORK:
Celsius helps over a million customers worldwide to find the path towards financial independence through a compounding yield service and instant low-cost loans accessible via a web and mobile app. Built on the belief that financial services should only do what is in the best interest of the customers and community, Celsius is a blockchain-based fee-free platform where membership provides access to curated financial services that are not available through traditional financial institutions. For additional information please visit www.celsius.network

ABOUT ANUBI DIGITAL:
Born in November 2020 and active in the Italian market since the end of 2021, Anubi Digital is a platform for passive and active custody of digital assets - including NFT - focused on serving the needs of the HNWI and institutional segments. Among the first companies in the world to provide access to institutional (permissioned) DeFi, Anubi Digital was founded by Diego D'Aquilio, active in the crypto world since 2015, Adriano Marconetto, over 20 years of experience in the tech world and Federico Nitidi, who has built businesses in Italy, Israel and the United States in the DeFi space.
www.anubidigital.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts:
Angélia Comunicazione
Simona Vecchies – Mob. +39 335 1245190
Paolo Frigerio – Mob. +39 348 5223239
Chiara Sandonato – Mob. +39 335 5635111
Email: anubidigital@angelia.it

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom